Haemonetics Corporation
Haemonetics Corporation (HAE) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Haemonetics Corporation (HAE), covering cash flow, earnings, and balance sheets.
Haemonetics Corporation (HAE) Income Statement & Financial Overview
Analyze Haemonetics Corporation’s HAE earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $330.60M | $348.54M | $345.51M | $336.17M |
| Cost of Revenue | $137.55M | $155.00M | $158.07M | $161.25M |
| Gross Profit | $193.05M | $193.55M | $187.44M | $174.92M |
| Gross Profit Ratio | $0.58 | $0.56 | $0.54 | $0.52 |
| R&D Expenses | $15.91M | $15.83M | $16.53M | $14.45M |
| SG&A Expenses | $115.36M | $106.46M | $106.95M | $107.98M |
| Operating Expenses | $131.27M | $134.52M | $135.74M | $122.44M |
| Total Costs & Expenses | $268.82M | $289.51M | $293.81M | $291.79M |
| Interest Income | $0.00 | $0.00 | $0.00 | $6.96M |
| Interest Expense | -$598000.00 | $9.11M | $6.99M | $6.96M |
| Depreciation & Amortization | $0.00 | $29.02M | $29.22M | $29.14M |
| EBITDA | $71.33M | $88.05M | $51.70M | $68.89M |
| EBITDA Ratio | $0.22 | $0.25 | $0.15 | $0.20 |
| Operating Income | $71.33M | $59.03M | $51.70M | $39.76M |
| Operating Income Ratio | $0.22 | $0.17 | $0.15 | $0.12 |
| Other Income/Expenses (Net) | -$598000.00 | -$9.11M | -$6.99M | $6.96M |
| Income Before Tax | $70.74M | $49.92M | $44.70M | $46.71M |
| Income Before Tax Ratio | $0.21 | $0.14 | $0.13 | $0.14 |
| Income Tax Expense | $12.76M | $12.42M | $10.87M | $8.34M |
| Net Income | $57.98M | $37.49M | $33.83M | $38.37M |
| Net Income Ratio | $0.18 | $0.11 | $0.10 | $0.11 |
| EPS | $1.17 | $0.75 | $0.66 | $0.75 |
| Diluted EPS | $1.17 | $0.74 | $0.66 | $0.74 |
| Weighted Avg Shares Outstanding | $49.19M | $50.29M | $50.90M | $50.94M |
| Weighted Avg Shares Outstanding (Diluted) | $49.48M | $50.64M | $51.24M | $51.56M |
The company's financials show resilient growth, with revenue advancing from $336.17M in Q1 2025 to $330.60M in Q4 2025. Gross profit remained healthy with margins at 58% in Q4 2025 compared to 52% in Q1 2025. Operating income hit $71.33M last quarter, sustaining a consistent 22% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $71.33M. Net income rose to $57.98M, while earnings per share reached $1.17. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan